Glossary

GLP-1 drug coverage

Whether a plan pays for GLP-1 medicines such as semaglutide, which often depends on the diagnosis the drug treats, plan rules and prior authorization.

Also called: GLP-1 agonist coverage, semaglutide coverage, weight-loss drug coverage, Ozempic coverage, Wegovy coverage

GLP-1 drugs are injectable (and some oral) medicines that mimic a gut hormone. Some are approved for type 2 diabetes and others for chronic weight management, and the same active ingredient can be sold under different brand names for each use. Coverage turns on which use the prescription is for, not on the drug alone.

Plans usually cover these drugs for diabetes through the formulary, often with prior authorization and quantity limits. Weight-loss coverage is far less consistent: many employer and individual plans exclude it, some cover it with conditions, and by statute Medicare Part D has long excluded drugs used for weight loss. In July 2026 CMS launched a Medicare GLP-1 Bridge, with a $50 monthly copay for weight-management GLP-1 drugs for Part D enrollees not already covered, available through December 31, 2027.

Say a plan puts a GLP-1 on a higher tier with a $60 copay per 28-day supply (a labeled hypothetical). That is $720 over twelve months, and a denial leaves you owing the full price.

Check the plan's formulary and exclusions before you start. A copay assistance program from the manufacturer may help only if your plan covers the drug.

Last reviewed November 16, 2026

In the index now

Related terms

Related guides

Related blog

Related insurers